HK1153934A1 - Gip-based mixed agonists for treatment of metabolic disorders and obesity gip - Google Patents
Gip-based mixed agonists for treatment of metabolic disorders and obesity gipInfo
- Publication number
- HK1153934A1 HK1153934A1 HK11108197.1A HK11108197A HK1153934A1 HK 1153934 A1 HK1153934 A1 HK 1153934A1 HK 11108197 A HK11108197 A HK 11108197A HK 1153934 A1 HK1153934 A1 HK 1153934A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- gip
- treatment
- obesity
- metabolic disorders
- based mixed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7327408P | 2008-06-17 | 2008-06-17 | |
US7817108P | 2008-07-03 | 2008-07-03 | |
US9044808P | 2008-08-20 | 2008-08-20 | |
US15134909P | 2009-02-10 | 2009-02-10 | |
PCT/US2009/047447 WO2010011439A2 (en) | 2008-06-17 | 2009-06-16 | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1153934A1 true HK1153934A1 (en) | 2012-04-13 |
Family
ID=41570802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11108197.1A HK1153934A1 (en) | 2008-06-17 | 2011-08-05 | Gip-based mixed agonists for treatment of metabolic disorders and obesity gip |
Country Status (28)
Country | Link |
---|---|
US (2) | US9062124B2 (de) |
EP (2) | EP2952202B1 (de) |
JP (2) | JP6108659B2 (de) |
KR (1) | KR20110040760A (de) |
CN (2) | CN102105159B (de) |
AR (1) | AR072159A1 (de) |
AU (1) | AU2009274425B2 (de) |
BR (1) | BRPI0915282A2 (de) |
CA (1) | CA2729296A1 (de) |
CL (1) | CL2009001425A1 (de) |
CO (1) | CO6280539A2 (de) |
CR (1) | CR11849A (de) |
DK (1) | DK2300035T3 (de) |
EA (1) | EA020326B9 (de) |
EC (1) | ECSP10010684A (de) |
ES (2) | ES2558842T3 (de) |
HK (1) | HK1153934A1 (de) |
HU (1) | HUE028072T2 (de) |
IL (1) | IL209666A (de) |
MA (1) | MA32397B1 (de) |
MX (1) | MX2010013453A (de) |
NZ (2) | NZ589848A (de) |
PE (1) | PE20100056A1 (de) |
PL (1) | PL2300035T3 (de) |
SG (1) | SG192405A1 (de) |
TW (1) | TWI474835B (de) |
WO (1) | WO2010011439A2 (de) |
ZA (1) | ZA201008807B (de) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2507098T3 (es) | 2005-11-07 | 2014-10-14 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
AU2008205229B2 (en) | 2007-01-05 | 2014-03-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
JP5771005B2 (ja) | 2007-10-30 | 2015-08-26 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | グルカゴンアンタゴニスト及びglp−1アゴニスト活性を示す化合物 |
CA2707861A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
JP2011511778A (ja) * | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
BRPI0907077A2 (pt) | 2008-03-26 | 2016-07-26 | Oramed Ltd | métodos e composições para administração oral de proteínas |
CN102026646A (zh) | 2008-05-05 | 2011-04-20 | 奥拉姆德有限公司 | 用于口服给予艾塞那肽的方法和组合物 |
PL2300035T3 (pl) | 2008-06-17 | 2016-04-29 | Univ Indiana Res & Tech Corp | Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości |
EP2300037B1 (de) | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Coagonisten des glucagon/glp-1 rezeptors |
MX2010012695A (es) | 2008-06-17 | 2011-03-15 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico. |
SG172291A1 (en) | 2008-12-19 | 2011-07-28 | Univ Indiana Res & Tech Corp | Amide based glucagon superfamily peptide prodrugs |
WO2010118034A2 (en) * | 2009-04-06 | 2010-10-14 | Board Of Regents, The University Of Texas System | Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells |
KR20120087875A (ko) * | 2009-06-16 | 2012-08-07 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체-활성 글루카곤 화합물 |
HUE026255T2 (en) | 2009-07-13 | 2016-06-28 | Zealand Pharma As | Acylated glucagon analogues |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
IN2012DN06437A (de) * | 2010-01-27 | 2015-10-09 | Univ Indiana Res & Tech Corp | |
AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
RU2604067C2 (ru) | 2010-05-13 | 2016-12-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов |
CN103179976A (zh) | 2010-05-13 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 呈现g蛋白偶联受体活性的胰高血糖素超家族肽 |
KR20130102470A (ko) | 2010-06-24 | 2013-09-17 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그 |
US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
JP5894174B2 (ja) | 2010-11-03 | 2016-03-23 | アレコー リミテッド | グルカゴンを含む新規組成物 |
US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
MX2013007327A (es) * | 2010-12-22 | 2014-01-08 | Marcadia Biotech Inc | Metodos para tratar transtornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de gip y glp-1. |
KR20140020292A (ko) | 2011-03-28 | 2014-02-18 | 노보 노르디스크 에이/에스 | 신규 글루카곤 유사체 |
EP2694095B1 (de) | 2011-04-05 | 2018-03-07 | Longevity Biotech, Inc. | Zusammensetzungen mit glukagon-analogen sowie verfahren zu ihrer herstellung und verwendung |
KR102002783B1 (ko) * | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
MX347703B (es) | 2011-06-22 | 2017-05-09 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1. |
US8729017B2 (en) | 2011-06-22 | 2014-05-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
MY167234A (en) | 2011-09-23 | 2018-08-14 | Novo Nordisk As | Novel glucagon analogues |
JP6324315B2 (ja) * | 2011-11-17 | 2018-05-16 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
US10342764B2 (en) | 2012-02-01 | 2019-07-09 | Oramed Ltd. | Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same |
TR201815338T4 (tr) * | 2012-05-03 | 2018-11-21 | Zealand Pharma As | Gıp-glp-1 dual agonist bileşikleri ve yöntemler. |
CN107739409A (zh) | 2012-05-18 | 2018-02-27 | 爱德迪安(北京)生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
CA2877358A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
PE20150863A1 (es) * | 2012-06-21 | 2015-06-11 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben actividad de receptor de gip |
CA2877363A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
ES2620111T3 (es) | 2012-07-23 | 2017-06-27 | Zealand Pharma A/S | Análogos de glucagón |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
HUE038748T2 (hu) | 2012-12-21 | 2018-11-28 | Sanofi Sa | Exendin-4 származékok, mint duális GLP1/GIP- vagy trigonális GLP1/GIP/glukagon-agonisták |
CN104902921A (zh) * | 2013-01-03 | 2015-09-09 | 奥拉姆德有限公司 | 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物 |
EP2970511B1 (de) | 2013-03-14 | 2020-09-30 | Indiana University Research and Technology Corporation | Insulin-inkretin-konjugate |
WO2014152460A2 (en) * | 2013-03-15 | 2014-09-25 | Indiana University Research And Technology Corporation | Prodrugs with prolonged action |
WO2014147124A1 (en) | 2013-03-21 | 2014-09-25 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
DK2976325T3 (en) | 2013-03-21 | 2017-06-06 | Sanofi Aventis Deutschland | SYNTHESIS OF PEPTIDE PRODUCTS CONTAINING CYCLIC IMID |
WO2014161835A1 (en) | 2013-04-03 | 2014-10-09 | Sanofi | Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof |
RS59124B1 (sr) | 2013-04-18 | 2019-09-30 | Novo Nordisk As | Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu |
MA38472B1 (fr) * | 2013-05-28 | 2018-09-28 | Takeda Pharmaceuticals Co | Composé peptidique |
WO2015022420A1 (en) * | 2013-08-16 | 2015-02-19 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
WO2015035419A1 (en) * | 2013-09-09 | 2015-03-12 | Hoffmann-La Roche Inc. | Dosages of gip/glp-1 co-agonist peptides for human administration |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
TWI666220B (zh) | 2013-10-17 | 2019-07-21 | 丹麥商西蘭製藥公司 | 醯化升糖素類似物 |
MX369770B (es) * | 2013-11-06 | 2019-11-21 | Zealand Pharma As | Compuestos agonistas triples de glucagón-glp-1-gip. |
KR102310389B1 (ko) * | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | Gip-glp-1 이원 효능제 화합물 및 방법 |
AU2014359894B2 (en) | 2013-12-06 | 2020-09-17 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
WO2015086732A1 (en) * | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues |
TW201609799A (zh) * | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
EP3080149A1 (de) | 2013-12-13 | 2016-10-19 | Sanofi | Duale glp-1-/glucagon-rezeptoragonisten |
EP3080150B1 (de) * | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten |
TW201609800A (zh) * | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 做為雙重glp-1/升糖素受體促效劑之艾塞那肽-4胜肽類似物 |
TW201609796A (zh) * | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
AR098614A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Compuesto para el tratamiento de hipoglicemia severa |
CN106029087A (zh) | 2013-12-20 | 2016-10-12 | 印第安纳大学研究及科技有限公司 | 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽 |
KR20160114082A (ko) | 2014-02-18 | 2016-10-04 | 노보 노르디스크 에이/에스 | 안정한 글루카곤 유사체 및 저혈당증의 치료를 위한 용도 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー/エス | 医療用のglp−1/グルカゴン受容体コアゴニスト |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
ES2822994T3 (es) * | 2014-09-24 | 2021-05-05 | Univ Indiana Res & Tech Corp | Conjugados de incretina-insulina |
AU2015335828B2 (en) | 2014-10-24 | 2018-08-23 | Merck Sharp & Dohme Llc | Co-agonists of the glucagon and GLP-1 receptors |
EP3212218B1 (de) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip-agonisten-verbindungen und -verfahren |
WO2016077220A1 (en) * | 2014-11-10 | 2016-05-19 | Mb2 Llc | Gip/glp-1 co-agonist peptides for human administration |
JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
TW201639878A (zh) | 2014-12-30 | 2016-11-16 | 韓美藥品股份有限公司 | 具有改善之安定性的升糖素衍生物 |
CN107636010B (zh) | 2015-04-16 | 2021-10-01 | 西兰制药公司 | 酰化胰高血糖素类似物 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
AU2016287209B2 (en) | 2015-06-30 | 2023-03-02 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
PT3398961T (pt) | 2015-12-31 | 2022-09-05 | Hanmi Pharm Ind Co Ltd | Ativador triplo ativando recetor glucagon, glp-1 e gip |
CN109477094B (zh) | 2016-05-24 | 2022-04-26 | 武田药品工业株式会社 | 肽化合物 |
GB201611077D0 (en) | 2016-06-24 | 2016-08-10 | Arecor Ltd | Novel composition |
NZ750267A (en) * | 2016-06-29 | 2023-12-22 | Hanmi Pharm Ind Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
CN109200273B (zh) * | 2017-07-04 | 2021-02-19 | 中国药科大学 | 一种多肽用于制备预防或治疗脂肪肝病药物的用途 |
TW201833131A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為胜肽類glp1/升糖素/gip受體促效劑之新化合物 |
AR110300A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
GB201620611D0 (en) * | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
WO2018104263A1 (en) | 2016-12-06 | 2018-06-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
WO2019183577A1 (en) * | 2018-03-23 | 2019-09-26 | Carmot Therapeutics, Inc. | Modulators of g-protein coupled receptors |
EP3774838B1 (de) | 2018-04-10 | 2022-08-10 | Sanofi-Aventis Deutschland GmbH | Lixisenatidsynthese mit verkappung |
BR112020020652A2 (pt) | 2018-04-10 | 2021-03-02 | Sanofi-Aventis Deutschland Gmbh | método para clivagem de peptídeos ligados à fase sólida a partir da fase sólida |
TWI707865B (zh) | 2018-05-04 | 2020-10-21 | 丹麥商諾佛 儂迪克股份有限公司 | Gip衍生物及其用途 |
TW202015735A (zh) | 2018-05-30 | 2020-05-01 | 法商賽諾菲公司 | 包含glp-1/升糖素/gip三重受體促效劑、連接子及透明質酸之接合物 |
JP2022500483A (ja) | 2018-09-24 | 2022-01-04 | 武田薬品工業株式会社 | Gip受容体アゴニストペプチド化合物及びその使用 |
WO2021083306A1 (zh) * | 2019-10-31 | 2021-05-06 | 东莞市东阳光生物药研发有限公司 | Glp-1/gcg双受体激动剂多肽 |
CA3184717A1 (en) | 2020-07-22 | 2022-01-27 | Patrick J. KNERR | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
JP2023534130A (ja) | 2020-07-22 | 2023-08-08 | ノヴォ ノルディスク アー/エス | Glp-1受容体およびgip受容体共作動薬 |
EP4236991A1 (de) | 2020-10-30 | 2023-09-06 | Novo Nordisk A/S | Triple agonisten des glp-1, gip und glucagonrezeptors |
CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
CR20230530A (es) | 2021-05-13 | 2024-02-19 | Carmot Therapeutics Inc | Moduladores de los receptores acoplados a proteínas g. |
IL309067A (en) * | 2021-06-09 | 2024-02-01 | Scripps Research Inst | Long-range dual GIP/GLP-1 peptide conjugates and methods of use |
WO2023030444A1 (zh) * | 2021-09-02 | 2023-03-09 | 广东东阳光药业有限公司 | Glp-1/gip双靶多肽、融合蛋白及其应用 |
TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
CN117186206A (zh) * | 2023-10-20 | 2023-12-08 | 广东药科大学 | 新型不同glp1类似肽共价聚合体及其制备方法和应用 |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275152A (en) * | 1977-02-03 | 1981-06-23 | Eastman Kodak Company | Hydrolysis of protein-bound cholesterol esters |
PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
EP0272253A4 (de) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | Verfahren zur verbesserung der glykoproteinstabilität. |
JPH04504416A (ja) * | 1989-02-17 | 1992-08-06 | コセルコ・ミモトープス・ピィ・ティ・ワイ.エル・ティ・ディ. | ペプチドの使用方法と合成方法 |
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
EP0512042B1 (de) | 1990-01-24 | 1998-04-08 | BUCKLEY, Douglas I. | Glp-1-analoga verwendbar in der diabetesbehandlung |
CA2024855C (en) | 1990-09-07 | 1997-12-09 | Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee | Process and intermediates for producing glucagon |
JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Gip様活性を有するポリペプチド誘導体及びその用途 |
US5510459A (en) * | 1991-01-17 | 1996-04-23 | Zymogenetics, Inc. | Glucagon antagonists |
ES2085004T3 (es) * | 1991-01-17 | 1996-05-16 | Zymogenetics Inc | Metodos para detectar antagonistas de glucagon. |
US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5480867A (en) * | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
JPH0940699A (ja) * | 1995-07-28 | 1997-02-10 | Sanwa Kagaku Kenkyusho Co Ltd | ポリペプチド及びその用途 |
DE19530865A1 (de) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
AU2263197A (en) | 1996-02-06 | 1997-08-28 | Eli Lilly And Company | Diabetes therapy |
KR100600457B1 (ko) | 1996-06-05 | 2006-07-13 | 로셰 디아그노스틱스 게엠베하 | 엑센딘 유사체, 이의 제조방법 및 이를 함유한 약제 |
JP2001505872A (ja) | 1996-09-09 | 2001-05-08 | ジーランド ファーマシューティカルズ アクティーゼルスカブ | α―ヒドロキシ酸リンカーを含むペプチドプロドラッグ |
UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
WO1998024464A1 (en) | 1996-12-03 | 1998-06-11 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
CA2321026A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
US20030236190A1 (en) * | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
WO2000020592A1 (en) | 1998-10-07 | 2000-04-13 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
JP3702181B2 (ja) * | 1998-12-07 | 2005-10-05 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Glp−1の類似体 |
WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
PT1171465E (pt) * | 1999-03-29 | 2004-12-31 | Uutech Ltd | Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes |
WO2000069911A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
EP1076066A1 (de) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptide zur Senkung des Blutglukosespiegels |
AU2001257278A1 (en) | 2000-04-27 | 2001-11-07 | Bionebraska, Inc. | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose |
US6677136B2 (en) * | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
AU2001269833A1 (en) * | 2000-06-14 | 2001-12-24 | Cytovax Biotechnologies, Inc. | Use of coiled-coil structural scaffold to generate structure-specific peptides |
KR100847615B1 (ko) | 2000-06-16 | 2008-07-21 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드-1 유사체 |
EP1305338A2 (de) | 2000-08-02 | 2003-05-02 | Theratechnologies Inc. | Modifizierte peptide mit erhöhter wirksamkeit |
US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
EP1324779B1 (de) * | 2000-09-29 | 2011-07-20 | Schering Corporation | Pegyliertes interleukin 10 |
WO2002048192A2 (en) | 2000-12-13 | 2002-06-20 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
ATE408414T1 (de) | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
EP1572885A2 (de) * | 2001-08-08 | 2005-09-14 | Genzyme Corporation | Verfahren zur behandlung von diabetes und anderer blutzuckerstörungen |
WO2003020201A2 (en) | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
US7041646B2 (en) * | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
AR036711A1 (es) * | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
US6864069B2 (en) | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
BR0213377A (pt) * | 2001-10-18 | 2006-05-23 | Bristol Myers Squibb Co | mìmico de peptìdeo semelhante ao glucagon 1 humano e seu uso no tratamento de diabetes e condições relacionadas |
CA2463803A1 (en) | 2001-10-19 | 2003-05-01 | Eli Lilly And Company | Biphasic mixtures of glp-1 and insulin |
EP1461069A2 (de) * | 2001-12-29 | 2004-09-29 | Novo Nordisk A/S | Kombinierte verwendung einer glp-1-verbindung und eines anderes medikaments zur behandlungv on dyslipidämie |
CA2468700A1 (en) | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
WO2003103572A2 (en) | 2002-06-04 | 2003-12-18 | Eli Lilly And Company | Modified glucagon-like peptide-1 analogs |
JP2006502100A (ja) | 2002-06-11 | 2006-01-19 | エーザイ株式会社 | 細胞の異常消失に関わる障害の治療のための、および/または、肥満の治療のためのgip活性を有する化合物の使用 |
BR0311843A (pt) | 2002-06-15 | 2005-03-15 | Enteromed Inc | Métodos para prevenir, inibir, tratar ou reduzir esteatose hepática não- alcoólica em um animal e para prevenir o desenvolvimento e/ou a reversão do processo de nafld em um animal |
CA2497794A1 (en) | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
US7192922B2 (en) * | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
EP2368578A1 (de) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür |
US20050059605A1 (en) | 2003-01-31 | 2005-03-17 | Krishna Peri | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
EP1594529B1 (de) * | 2003-02-19 | 2010-01-20 | Ipsen Pharma | Glp-1-analoga |
WO2004078777A2 (en) | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
PL1605897T3 (pl) | 2003-03-19 | 2012-12-31 | Lilly Co Eli | Związki będące połączeniem GLP-1 z poli(glikolem etylenowym) |
CA2843439A1 (en) * | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd | Reversible pegylated drugs |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7259234B2 (en) | 2003-05-15 | 2007-08-21 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
CA2527743A1 (en) | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
JP2007524592A (ja) | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー/エス | 安定化された薬学的ペプチド組成物 |
PL1641823T3 (pl) * | 2003-06-12 | 2012-02-29 | Lilly Co Eli | Białka fuzyjne analogu GLP-1 |
US20050124550A1 (en) * | 2003-06-18 | 2005-06-09 | Peri Krishna G. | Compounds that modulate the glucagon response and uses thereof |
SI2932981T1 (sl) * | 2003-09-19 | 2021-11-30 | Novo Nordisk A/S | Albumin-vezavni derivati GLP-1 |
US7364875B2 (en) * | 2003-10-30 | 2008-04-29 | Cresent Innovations, Inc. | Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight |
DE602004026113D1 (de) * | 2003-12-18 | 2010-04-29 | Novo Nordisk As | Glp-1-verbindungen |
US20060286129A1 (en) * | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
US20080318837A1 (en) * | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
US8527752B2 (en) | 2004-06-16 | 2013-09-03 | Dormarke Assets Limited Liability | Graduated authentication in an identity management system |
JP4666342B2 (ja) | 2004-07-26 | 2011-04-06 | ルネサスエレクトロニクス株式会社 | 半導体集積回路装置 |
JP2008509692A (ja) * | 2004-08-16 | 2008-04-03 | ノボ ノルディスク アクティーゼルスカブ | ペプチドの多量体 |
US7442682B2 (en) * | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
EP2392595A1 (de) * | 2005-02-11 | 2011-12-07 | Amylin Pharmaceuticals Inc. | GIP-Analog und Hybridpolypeptide mit auswählbaren Eigenschaften |
US8263545B2 (en) * | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
EP1863537A2 (de) * | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Dimere peptidagonisten des glp-1-rezeptors |
WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
PL1881850T3 (pl) | 2005-05-13 | 2011-03-31 | Lilly Co Eli | Pegylowane związki GLP-1 |
DK1891105T3 (da) | 2005-06-13 | 2012-07-16 | Imp Innovations Ltd | Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd |
US7360772B2 (en) | 2005-07-20 | 2008-04-22 | Koch Hal D | Child transport air filtering system |
EP1922336B1 (de) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybridpolypeptide mit auswählbaren eigenschaften |
AU2006289259A1 (en) | 2005-09-08 | 2007-03-15 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
WO2007028633A2 (en) | 2005-09-08 | 2007-03-15 | Uutech Limited | Treatment of diabetes related obesity |
ES2507098T3 (es) | 2005-11-07 | 2014-10-14 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
EP1991574B1 (de) | 2006-02-22 | 2016-10-12 | Merck Sharp & Dohme Corp. | Oxyntomodulin-derivate |
ES2397659T3 (es) * | 2006-03-15 | 2013-03-08 | Novo Nordisk A/S | Mezclas de amilina e insulina |
JP5412273B2 (ja) * | 2006-03-21 | 2014-02-12 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | ペプチド−ぺプチダーゼ阻害剤及びその使用 |
WO2007124461A2 (en) * | 2006-04-20 | 2007-11-01 | Amgen Inc. | Glp-1 compounds |
WO2008022015A2 (en) | 2006-08-11 | 2008-02-21 | Trustees Of Tufts College | Retro-inverso incretin analogues, and methods of use thereof |
AU2007284365A1 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
WO2008023050A1 (en) | 2006-08-25 | 2008-02-28 | Novo Nordisk A/S | Acylated exendin-4 compounds |
US20080053857A1 (en) | 2006-08-31 | 2008-03-06 | Paul Vincent Enriquez Albano | Package having two different views for increased awareness in display |
EP2615108B1 (de) * | 2006-09-08 | 2016-10-26 | Ambrx, Inc. | Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen |
US8617531B2 (en) | 2006-12-14 | 2013-12-31 | Bolder Biotechnology, Inc. | Methods of making proteins and peptides containing a single free cysteine |
AU2008205229B2 (en) * | 2007-01-05 | 2014-03-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
US7994122B2 (en) * | 2007-06-15 | 2011-08-09 | Zealand Pharma A/S | Glucagon analogues |
US7859468B2 (en) * | 2007-08-30 | 2010-12-28 | Research In Motion Limited | Mobile wireless communications device including a folded monopole multi-band antenna and related methods |
EP2190872B1 (de) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptid-1-derivate und ihre pharmazeutische verwendung |
CN101842386A (zh) | 2007-09-05 | 2010-09-22 | 诺沃-诺迪斯克有限公司 | 截短的glp-1衍生物和它们的治疗用途 |
EP2650006A1 (de) | 2007-09-07 | 2013-10-16 | Ipsen Pharma S.A.S. | Analoga von Exendin-4 und Exendin-3 |
EP2036923A1 (de) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Verbesserte Derivate von Amylin |
WO2009034117A1 (en) | 2007-09-11 | 2009-03-19 | Novo Nordisk A/S | Mixture comprising an amylin peptide and a protracted insulin |
EP2036539A1 (de) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stabile Formulierungen aus Amylin und dessen Analogen |
JP5771005B2 (ja) * | 2007-10-30 | 2015-08-26 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | グルカゴンアンタゴニスト及びglp−1アゴニスト活性を示す化合物 |
CA2707861A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
US20090181037A1 (en) | 2007-11-02 | 2009-07-16 | George Heavner | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses |
JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
WO2009095479A2 (en) | 2008-02-01 | 2009-08-06 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker |
MX2010012695A (es) * | 2008-06-17 | 2011-03-15 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico. |
EP2300037B1 (de) | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Coagonisten des glucagon/glp-1 rezeptors |
PL2300035T3 (pl) | 2008-06-17 | 2016-04-29 | Univ Indiana Res & Tech Corp | Mieszani agoniści na bazie GIP do leczenia zaburzeń metabolicznych i otyłości |
JP2012512898A (ja) | 2008-12-19 | 2012-06-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | ジペプチド結合薬用剤 |
SG172291A1 (en) | 2008-12-19 | 2011-07-28 | Univ Indiana Res & Tech Corp | Amide based glucagon superfamily peptide prodrugs |
WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
KR20120087875A (ko) | 2009-06-16 | 2012-08-07 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체-활성 글루카곤 화합물 |
US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Axentomodulin polypeptide |
AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
IN2012DN06437A (de) | 2010-01-27 | 2015-10-09 | Univ Indiana Res & Tech Corp | |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
RU2604067C2 (ru) | 2010-05-13 | 2016-12-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов |
CN103179976A (zh) | 2010-05-13 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 呈现g蛋白偶联受体活性的胰高血糖素超家族肽 |
KR20130102470A (ko) | 2010-06-24 | 2013-09-17 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그 |
WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
-
2009
- 2009-06-16 PL PL09800752T patent/PL2300035T3/pl unknown
- 2009-06-16 DK DK09800752.9T patent/DK2300035T3/en active
- 2009-06-16 EP EP15175377.9A patent/EP2952202B1/de active Active
- 2009-06-16 NZ NZ589848A patent/NZ589848A/xx not_active IP Right Cessation
- 2009-06-16 BR BRPI0915282A patent/BRPI0915282A2/pt not_active IP Right Cessation
- 2009-06-16 AR ARP090102180A patent/AR072159A1/es not_active Application Discontinuation
- 2009-06-16 CN CN200980123349.1A patent/CN102105159B/zh active Active
- 2009-06-16 PE PE2009000874A patent/PE20100056A1/es not_active Application Discontinuation
- 2009-06-16 WO PCT/US2009/047447 patent/WO2010011439A2/en active Application Filing
- 2009-06-16 NZ NZ603445A patent/NZ603445A/en not_active IP Right Cessation
- 2009-06-16 CA CA2729296A patent/CA2729296A1/en not_active Abandoned
- 2009-06-16 AU AU2009274425A patent/AU2009274425B2/en not_active Ceased
- 2009-06-16 SG SG2013045547A patent/SG192405A1/en unknown
- 2009-06-16 ES ES09800752.9T patent/ES2558842T3/es active Active
- 2009-06-16 CL CL2009001425A patent/CL2009001425A1/es unknown
- 2009-06-16 EP EP09800752.9A patent/EP2300035B1/de active Active
- 2009-06-16 HU HUE09800752A patent/HUE028072T2/en unknown
- 2009-06-16 ES ES15175377.9T patent/ES2650038T3/es active Active
- 2009-06-16 US US12/999,285 patent/US9062124B2/en active Active
- 2009-06-16 EA EA201001801A patent/EA020326B9/ru not_active IP Right Cessation
- 2009-06-16 KR KR1020107028260A patent/KR20110040760A/ko not_active Application Discontinuation
- 2009-06-16 CN CN201510309638.8A patent/CN104945500B/zh active Active
- 2009-06-16 JP JP2011514735A patent/JP6108659B2/ja active Active
- 2009-06-16 MX MX2010013453A patent/MX2010013453A/es active IP Right Grant
- 2009-06-16 TW TW098120096A patent/TWI474835B/zh not_active IP Right Cessation
-
2010
- 2010-11-30 IL IL209666A patent/IL209666A/en not_active IP Right Cessation
- 2010-12-07 ZA ZA2010/08807A patent/ZA201008807B/en unknown
- 2010-12-15 MA MA33430A patent/MA32397B1/fr unknown
- 2010-12-16 CR CR11849A patent/CR11849A/es not_active Application Discontinuation
- 2010-12-16 EC EC2010010684A patent/ECSP10010684A/es unknown
- 2010-12-16 CO CO10158388A patent/CO6280539A2/es not_active Application Discontinuation
-
2011
- 2011-08-05 HK HK11108197.1A patent/HK1153934A1/xx not_active IP Right Cessation
-
2015
- 2015-04-02 JP JP2015076371A patent/JP6174071B2/ja active Active
- 2015-05-18 US US14/714,728 patent/US20150322130A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1153934A1 (en) | Gip-based mixed agonists for treatment of metabolic disorders and obesity gip | |
IL258730A (en) | Preparations and methods for the treatment of microbial disorders | |
EP2120580A4 (de) | Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen | |
EP2528618A4 (de) | Glucagon-antagonisten- und gip-agonisten-konjugate sowie zusammensetzungen zur behandlung von stoffwechselerkrankungen und adipositas | |
IL209032A0 (en) | Compositions and methods for treating digestive disorders | |
EP2424464A4 (de) | Vorrichtung und verfahren zur behandlung von magen-darm- und stoffwechselerkrankungen | |
EP2405755A4 (de) | Verfahren und zusammensetzungen zur behandlung von stoffwechsel- und herz-kreislauf-erkrankungen | |
IL194189A0 (en) | Combination treatment of metabolic disorders | |
HK1173654A1 (zh) | 治療化合物及相關的使用方法 | |
EP2194917A4 (de) | Vorrichtungen und verfahren zur behandlung von adipositas | |
HK1152939A1 (en) | Carboxamide compounds for the treatment of metabolic disorders | |
HK1150839A1 (en) | Compositions and methods of use for therapeutic antibodies | |
EP2205236A4 (de) | Neue mittel zur behandlung von erkrankungen und funktionsstörungen | |
GB0703909D0 (en) | Treatment of anxiety disorders | |
EP2217073A4 (de) | Verfahren zur behandlung von stoffwechselstörungen und depression mit dopaminrezeptoragonisten | |
EP2051732A4 (de) | Diagnose- und behandlungsverfahren für stoffwechselstörungen | |
EP2271352A4 (de) | Zusammensetzungen und verfahren zur behandlung von neoplastischen erkrankungen | |
HK1160598A1 (zh) | 治療腎功能紊亂的組合物和方法 | |
EP2285398A4 (de) | Verfahren und zusammensetzungen zur behandlung von adipositas | |
EP2600716A4 (de) | Verfahren und zusammensetzungen zur behandlung von stoffwechselerkrankungen | |
EP2142256A4 (de) | Behandlung von adipositas | |
EP2240024A4 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
IL207966A0 (en) | Compounds and methods of treating obesity | |
GB0813310D0 (en) | Treatment of obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190616 |